Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept in Autoimmune Cytopenias (RUBY-4)
NCT05757570Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Aug 2026
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 2 trial of povetacicept in immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), sponsored by Vertex Pharmaceuticals. Started Jul 2023; status: completed.
02
Drugs
povetacicept
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT05757570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757570.